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Summary Prostaglandin F2. (PGF2a) was determined by radioimmunoassay in 57 breast carcinomata, 16
fibroadenomata, and 33 sclero-cystic-disease (SCD) specimens. In 41 cases of carcinoma and 10 cases of
fibroadenoma, histologically non-malignant tissue was also obtained from the same breast. PGF2. levels were
significantly elevated in breast cancer when compared with the normal tissues and benign diseases (P<0.005
for each group). High PGF2, levels were positively correlated with differentiation, positive oestrogen and
progestagen receptor status, and low mitotic index. Tumours with good prognosis (<20mm, negative lymph
nodes, some degree of differentiation) showed significantly higher PGF2a levels than tumours with a bad
prognosis(>20mm, positive nodes and undifferentiated). A tendency for elevated PGF2. levels was observed
with negative lymphatic permeation, postmenopausal status, low grade of nuclear and cellular polymorphism
and high degree of elastosis and fibrosis. No correlation was observed between PGF2. levels and host-cell
reaction.
Plasma levels of 15-keto-13, 14-dihydro-PGF2., were not elevated in cancer patients when compared with
the SCD-group.
The present study demonstrates that PGF2. levels are high in tumours with good prognosis. However, since
other authors have suggested that a high PGE2 production is a bad prognostic index, it is possible that
conversion of PGE2 to PGF2. by 9-keto-reductase explains this relationship. Nevertheless, the presented
results question the unrestricted use ofprostaglandin-synthesis-inhibitors in the treatment of breast cancer.
Prostaglandins (PGs), especially of the E-series,
have been shown to be elevated in a large number
of human and experimental tumours. Special efforts
have been made to investigate the features and the
role of PG-synthesis in human breast cancer
(Bennett et al., 1975; Powles et al., 1976; Kibbey et
al., 1980; Greaves et al., 1980; Malachi et al., 1981;
Campbell et al., 1983).
A considerable volume of research on the
mechanisms of action of PGs in a wide variety of
cells and tissues, indicates that PGs are possibly
involved in tumour initiation, tumour promotion,
cell proliferation and differentiation, the immune
response, tumour metastasis, osteolysis and hyper-
calcaemia (Karmali, 1980; Honn et al., 1981a;
Droller, 1981; Goodwin, 1981).
The present study was designed to describe the
basic features of PGF2X, production in benign and
malignant breast tumours. Normal glandular breast
tissues were used as controls. We determined
PGF2<,, because this product is more stable than
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PGE2 and because prostaglandin F2, has not been
thoroughly investigated in human mammary
cancer.
In order to find out whether the high levels of
prostaglandin F2a found in cancerous tissues could
be correlated with either metastatic potential or
with other prognostic unfavourable variables, the
PGF2a, levels were examined in relation to the size
of the tumour, axillary lymph node status,
lymphatic vessel permeation, histological type and
differentiation of the tumour, mitotix index,
oestrogen and progestagen receptor status, and age
and menopausal status of the patient.
Tumour - associated host-cells can produce
considerable amounts of prostaglandins (Humes et
al., 1977; Brune et al., 1978). Therefore the
numbers of host-derived cells and the amount of
necrosis were evaluated by means of quantitative
microscopy. The epithelial cellularity was also
evaluated by morphometric determination of the
mean nuclear density and mean nuclear area.
Materials and methods
There were 165 specimens from 106 patients who
underwent surgery for a breast lump. Each
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specimen was divided into two representative parts
and immediately immersed, either in acetone cooled
by solid CO2 (-70°C) for PG-investigations, or in
Bouin's liquid for histopathological examination.
The tissue samples for PGF2a investigation were
then stored at -300C until radioimmunoassay was
performed. Sections 8pm thick were cut from the
stored routine embedded blocks, processed by
standard methods, and stained by haematoxylin
and eosin.
Fifty-seven tumours were diagnosed as primary
breast cancer (patient age range: 31 to 80y; mean:
56.6y). No patient had received chemotherapy or
radiotherapy at the time of biopsy. The patients
were classified according to the pathological TNM
system (UICC, Livre de Poche): pTiaNo16;
pTiaNlal; pTlaNlb6; pTlaN23; pTlbNol;
pT2.NOI1; pT2aNlal; pT2aNlblO; pT2aN22;
pT30Nlb5 and pT4Nlbl. Forty-nine tumours were
benign, including 16 fibroadenomata (age range: 17
to 52y; mean: 29.1y), and 33 sclero-cystoc-disease
specimens (age range: 30 to 62y; mean: 46.2y). The
PGF2,, levels were also investigated in two cellular
intracanalicular fibroadenomata.
Histologically proven normal breast tissue from
41 breasts with a carcinoma, and 10 from breasts
with an adenofibroma, were investigated. In
addition 6 lymph nodes, two of which showed
metastasis, were examined.
In blood removed at the time of surgery the
serum level of 15-keto-13, 14-dihydro-PGF2a, the
main metabolite of PGF2,, was measured in 11
cancer patients and in 16 patients with sclerocystic-
disease. The estimation of the PGF metabolite
rather than PGF2a as such was preferred, since the
former more closely reflects the true production in
vivo and is less liable to erroneous changes during
blood sampling.
The age and menopausal status of the patients
and the tumour size at anatomopathological
examination were recorded. Menopause was defined
as at least one year after the last menstrual period.
Twenty-one cancerous lesions were examined for
oestrogen and progestagen receptor status,
determined according to Noel et al. (1982). In our
laboratory, the oestrogen receptor status and
progestagen receptor status are considered positive
for levels higher than 10 and 100fmolemg'-
protein respectively.
The PGF2. amounts were expressed as
ngPGF2.mg-1 protein and as ngPGF2a per
cellularity index (g wet w tissue divided by the
mean nuclear density). The number of evaluated
sam'ples is higher when the cellularity index is used,
as there was not always enough tissue to measure
the protein content. Also, the histological variables
could not always be measured.
Histopathology
The slides were independently reviewed by three of
the authors and were re-evaluated by a senior
pathologist in cases of discordance. The results of
the PG investigation were not known at that time.
Histological type, differentiation, infiltration,
fibrosis, elastosis, host-cell reaction, lymph node
metastasis, lymphatic vessel invasion, nuclear and
cellular polymorphism and nuclear: cytoplasmic
ratio, were independently evaluated.
Tumours were classified according to the WHO
classification (1981). Whenever there was a
combination of more than one histological type, the
tumour was assigned to the group to which its most
extensive component belonged. Tumours with a
high amount of intraductal necrosis were classified
as comedocarcinomata (Haagensen, 1971). The
malignant tumours were graded according to
Bloom & Richardson (1957).
Inflitration, fibrosis, elastosis and host-cell
reaction were determined as negative, mild,
moderate or strong. Nuclear and cellular
polymorphism were calssified as mild, moderate or
strong. The nuclear: cytoplasmic ratio was recorded
as small, moderate or high.
Axillary lymph node status was recorded positive
or negative depending on whether cancerous cells
were present or not. Lymphatic vessel permeation
was recorded as positive when cancerous cells were
present in the lymphatic vessels in the tumour, or
when the lymph node status was positive.
Quantitative microscopy
Nuclear density of the carcinomatous cells, nuclear
size, mitotic index and necrosis, were evaluated
morphometrically, according to Weibel (1979),
using a planimeter (Kontron - MOP AM 02) and a
microprocessor (HP 98 15 A).
The necrosis and total area of all the
carcinomatas were determined with semi-automatic
histomorphometry. Presence of necrosis was
evalulated as percentage of the total area of re-
presentative tumour tissue.
Mean nuclear density and mean nuclear area of
the malignant epithelial cells were counted on a
projection microscope at x 400 magnification using
the planimeter and microprocessor. Twenty areas of
6680pm2 were counted according to Weibel (1979).
The numbers of mitoses were counted in 20
random fields at x 400 magnification. Once
focussed, no further adjustment was allowed and
the structures that could be differently interpreted
were not counted. The mitotic index was expressed
as the mean of the number of mitoses counted in
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Radioimmunoassay ofPGF2a
Before radioimmunoassay of PGF2a the acetone
was evaporated under nitrogen and the weight of
the tissue determined. Tris buffer (50 M, pH=8.00
at 25°C) was added (3mlg-' tissue) and sonicated
for 90min (Bransonic). Ice was regularly added to
the bath fluid of the sonication apparatus to keep
temperature below 10°C. The supernatant was
separated from the tissue after centrifugation at
10,OOOg (Eppendorf centrifuge). The extraction yield
for PG was checked by adding trace amounts of
radiolabelled standards.
Incubation of thawed and N2-dried tissues
(30min, 37°C) with radioactive "4C arachidonic
acid (n=5) showed almost complete inactivation of
cyclo-oxygenase after acetone (-70°C) treatment
since 95-98% of the substrate remained intact.
Samples (0.2ml and 0.1 ml) were run in an
adapted radioimmunoassay according to Granstrom
& Kindahl (1978), using an antiserum which we
produced in a final dilution of 1/17500. Cross
reactivities at 50% of the binding curve were:
PGF,,, 6.9%; 6-oxo-PGF,,, TXB2, PGE2 and 15-
keto-13, 14-di-hydro-PGF2', <0.001%.
A precipitate was formed with bovine-y-globulin
after adding polyethyleneglycol (PEG) 4000. Radio-
activity was counted in a Packard 460 scintillation
counter with quench correction. The protein
content of the breast tissue extracts was determined
(Bradford, 1976) and the PGF2a content expressed
as ngPGmg- ' protein.
During surgery citrate plasma was collected from
some patients with SCD or breast cancer. The
plasma (0.5ml and 0.2ml) was analysed (RIA) for
15-keto-13,14-dihydro-PGF2a, using the antiserum
which we produced, in a final dilution of 1/7000.
The cross-reactivities at 50% of the binding curve
were: 6, 15-diketo-13, 14-dihydro-PGF2a 21%; 6, 15-
diketo-PGF,,, 3.3%; PGF1., 0.2%; PGF2a, 0.04%;
6-keto-PGF,1, 0.03%; PGE2, TXB2<0.001%.
The extraction yield of PGF2a from the
specimens was 80.8+4.1% (n=6), calculated by
adding trace amounts of radioactive PGF2 to the
tissues.
Reagents
PGF2a and 15-keto-13, 14-dihydro prostaglandin
F2. (Upjohn), [3H]-radiolabelled PGF2a(NEN),
[3H]-radiolabelled 15-keto-13,14-dihyrdo-PGF2.,
trizmn base and trizma HCI (Sigma), polyethylene-
glycol 4000 (Purna), Instagel (Packard), bovine-y-
globulin (Sigma).
Statistical analysis
The used statistical test were: Wilcoxon (u value),
one way analysis of variance (ANOVA; F value)
and significance of the correlation coefficient (linear
regression; t value) (Goldstein, 1964). When no
statistical test is mentioned, the Wilcoxon test was
used to compare two groups of samples.
Results
PGF2a levels in relation to the histopathological groups
The results according to the different histopath-
ological groups are shown in Figure 1 and are
analysed statistically in Table I. The PGF2a yield
from malignant tissue (CA) was higher than from
non-malignant tissues from breast with a carcinoma
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Figure 1 PGF2,, levels extracted from biopsies of
normal and pathological breast tissue. CA=malignant
tumours (n=57). N-CA = apparently normal tissue
from a breast with a carcinoma (n=41). SCD =sclero-
cystic-disease tissues (n=33). FA =fibradenomata
(n= 16). N=normal breast tissue (n=10). Median
values are indicated.
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Table I Comparison of the PGF2a yield between the various
histopathological groups.
Group PGF2a Group PGF2a P-value
CA (57) 15.00+2.35 N-CA (41) 0.95+0.27 <0.005
FA (16) 2.20+0.57 <0.005
SCD (33) 2.33+0.92 <0.005
N (10) 0.66+0.21 <0.005
N (10) 0.66+0.21 FA (16) 2.20+0.57 <0.005
N-CA (41) 0.95+0.27 0.44
SCD (33) 2.33+0.92 0.10
The PG results are given as mean+s.e., and expressed as ngmg-
protein. The number of evaluated samples is given in brackets. CA:
carcinoma N-CA: histologically non-malignant tissue from a breast
with a carcinoma. FA: fibroadenoma. N: normal glandular breast
tissue. SCD: sclerocystic disease.
(N-CA), fibroadenomata (FA), sclero-cystic-disease
tissues (SCD) and normal glandular breast tissues
(N) (all P<0.0003).
Amounts from fibroadenomata (FA) were higher
than from normal glandular breast tissues (N)
(P=0.002). We found no difference in the PGF2a
yields from the N and N-CA groups (P =0.43).
PGF2a yield tended to be higher from SCD
specimens than from N specimens (P=0.069).
In 12 out of 26 patients a measurable 15-keto-
13,14-dihydro-PGF2. level was found, i.e.
>25pgml-P. Only 3 patients showed plasma levels
>100pgml-P (475, 456 and 1065pgml-'). We
found no correlation between plasma levels of 15-
keto-13, 14-dihydro-PGF2a and PGF2e breast tissue
levels. There was no apparent difference between
the plasma levels found in the CA group and the
SCD group.
Relationship between the breast cancer PGF2a levels
and the different prognostical variables
Tumour oestrogen and progestagen receptor contents
Oestrogen-positive tumours yielded more
PGF2 mg- 1 protein, than did oestrogen-negative
tumours (P=0.004); progesterone-positive tumours
yielded more PGF2amg- 1 protein (P =0.05) and
per cellularity index (P=0.037) (Table II and Figure
2).
Tumour size PGF2. levels tended to correlate
inversely with the tumour size (r=0.106, P=0.33)
(Table III).
Age and menopausal status Tumour PGF2a
levelsmg'- protein tended to be higher with older
patients (>60 years) (ANOVA; F = 2.70; P =0.06),
and with the cellularity index the P value was 0.03
(ANOVA; F =3.33).
There was no significant difference between
tumour PGF2. levels of pre- and postmenopausal
patients (P=0.29) (Table III).
Histological type and differentiation Statistical
analysis of all the histological types was difficult,
because the infiltrating ductal carcinomatas
composed the only substantial group. They yielded
more PGF2a than did the other histological types
(Table IV). The two cellular intracanalicular fibro-
adenomata yielded 0.2 and 4.0ng PGF2amg-
protein respectively.
Histological differentiation was recorded as small,
moderate or high. For statistical analysis we divided
Table II PGF2. yields from breast cancers in relation to
steroid receptors and differentiation.
Variable PGF2. P-value
Oestrogen pos(12) 15.04+2.96 0.004
receptors neg (9) 5.54+1.07
Progesterone pos(l5) 12.78 +2.62 0.05
receptors neg (6) 6.43+1.72
Differentiation undiff(28) 8.06+ 1.40 0.004
diff(24) 14.80+2.14
The PG results are given as ngmg-1 protein, mean+s.e.
The number ofevalulated samples is given in brackets.
Oestrogen receptor pos=oestrogen receptor contents >
10fmolmg -1 protein
Oestrogen receptor neg=oestrogen receptor content<
10fmolmg - I protein
Proesterone receptor pos=progesterone receptor con-
tent .100fmolmg-' protein
Progesterone receptor neg=progesterone receptor con-
tent<100fmolmg-I protein
Differentiation undiff=undifferentiated
diff=some degree ofdifferentiation
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Figure 2 Relationship between progestagen and
oestrogen receptors and PGF2U levels. The PG results
are given as mean + s.e. The figures at the bottom
represent the number of patients evaluated. (El)
Progesterone receptors (-)= 100fmolmg- protein.
(+) = > 100fmolmg-1 protein. ( A) Oestrogen
receptors (-) = _ 10fmol mg -' protein. (+) =
>10fmolmg-' protein. ng PGF2a/cellularity index=
ng PGF2,g- 1 wet tissue w/mean nuclear density.
(*:P=or <0.05; **P<0.005; When no
* is indicated:
P >0.05).
*the tumours into two groups: undifferentiated and
some degree of differentiation (small, moderate or
high). The tumours with some degree of differen-
tiation yielded more PGF2a than did the undifferen-
tiated tumours (P =0.004, ng mg 1 protein; P =0.013,
ng cellularity index-1) (Table II and Figure 3).
ANOVA between the various groups with some
degree of differentiation showed no significant
differences (F=0.16, P=0.85).
Lymph node metastasis and lymphatic vessel
permeation We found, at most, a weak tendency
for higher PGF2a levels in the lymph node negative
group compared with the node positive group
(P =0.189) (Table III). PGF2a was determined in 6
lymph nodes, the values for the negative lymph
nodes being 0.1, 7.7, 1.9 and 9.2 ngmg-1 protein;
those for the positive lymph nodes were 3.3 and
9.7 ngmg'- protein.
Lymphatic vessel permeation was present in 82%
of the cases and there was little or no difference
(P =0.209) between this group and the small negative
group (Table III).
Size and density of nuclei of carcinoma cells We
observed no correlation between the PGF2a levels
and the mean nuclear density or size (P=0.32; r=
-0.064 and P=0.49; r= -0.002 respectively). We
observed also no correlation with the mean nuclear
area (P =0.30; r =0.076).
Mitotic index The mitotic index correlated
inversely with the ngPGF2amg- protein (P=0.05;
r= -0.227), but when the cellularity index was
used, the significance was P= 0.13 (r= -0.159).
Table III PGF2., yields from primary breast cancer in
relation to several variables
Variable
Tumour size<20mm (25)
20-<39mm (21)
.40mm (7)
Menopausal status pre (21)
post (32)
Lymph nodes negative (25)
positive (28)
Lymphatic permeation negative (7)
positive (46)
Nuclear and cellular polymorphism
mild (7)
moderate (33)
strong (13)
Nuclear cytoplasmic ratio:
small (10)
moderate (34)
high (9)
aHost cell reaction:
mild (28)
moderate (12)
strong (8)
aMast cells:
absent (11)
present (17)
Necrosis 0% (9)
>0% (25)
. 1% (19)
Fibrosis:
mild (17)
moderate (25)
marked (11)
Elastosis:
0 (32)
mild (14)
moderate (5)
marked (2)
Infiltration:
0 (1)
mild (0)
moderate (12)
strong (39)
marked (1)
PGF2a yield
11.72+2.42
10.91+ 1.72
9.31 +2.76
9.89+ 1.45
11.93+1.81
17.18+4.15
12.26+2.65
11.90+2.93
9.91 + 1.17
14.20+4.47
10.55+ 1.61
9.48+ 1.93
10.55+2.44
11.91 + 1.74
7.07+ 1.45
13.67+1.88
9.07+2.59
7.59 + 1.33
8.50+ 1.57
12.40+2.64
10.77+3.62
10.24+1.84
11.38+ 1.95
9.54+1.90
10.53+ 1.89
12.66+3.20
8.35+0.97
14.37 +3.56
18.62+3.69
2.7 and 10.0
21
7.53 + 1.35
12.01 + 1.55
4.5
The PG results are given as ngmg-' protein, mean+
s.e.m. The number ofevaluated samples is given in brackets.
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Table IV PGF2ar yields from breast cancer in relation to
histological type
Histological type PGF2a,
Infiltrating ductal undiff (19) 9.72+ 1.92
diff (24) 14.80+2.14
Lobular (5) 3.38 +0.44
Comedo (3) 2.3 to 11.2a
Medullary (1) 6.0
Mucoid (1) 4.5
The PG results are given as ngmg- protein,
mean+s.e.m. The number of evalulated samples is given
in brackets.
Undiff=undifferentiated.
Diff =some degree of differentiation (small, moderate
or high).
a =limit values.
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Figure 3 Relationship between the degree of
differentiation and PGF24 levels. The PG results are
given as mean+s.e. The number of patients evaluated
is indicated at the bottom. - = undifferentiated; + to
+ + + =some degree of differentiation (mild, moderate
or high). ng PGF2X/cellularity index=ng PGF2,,g1
wet tissue w/mean nuclear denisty. (*P<0.05).
Nuclear and cellular polymorphism and the nuclear:
cytoplasmic ratio Tumours with a low degree of
nuclear and cellular polymorphism and a low
nuclear: cytoplasmic ratio showed at most a weak
tendency to yield more PGF2. (ANOVA, F=0.60;
P=0.55; and F= 1.64, P=0.20 respectively) (Table
III).
Host cell reaction and necrosis PG levels tended to
correlate inversely with the host-cell reaction
(ANOVA, F=2.01, P=0.15), but there was little
or no relationship to the presence of mast cells
(P=0.37), or to the amount of necrosis (ANOVA,
F=0.13; P=0.88) (Table III).
Elastosis, fibrosis and infiltration PGF2a values in
tumours with elastosis, fibrosis or infiltration
showed at most a week tendency to be higher
(Wilcoxon, P=0.10; ANOVA, F=0.67, P=0.52;
Wilcoxon, P=0.27 respectively).
Cumulation of variables A gradual increase in
statistical significance occurred when several
characteristics were combined. Mean PGF2a levels
ngmg 1 protein tended to be higher when the
lymph nodes were negative (P= 0.189), and the
relationship marginally strengthens when tumours
<20mm with negative lymp nodes are compared
with tumours >20mm with positive lymph nodes
(P=0.104). Tumours with some degree ofdifferentia-
tion <20mm and with negative lymph nodes yielded
more PGF2a than did undifferentiated tumours
>20mm with positive lymph nodes (P=0.045)
(Table V).
Discussion
The present study has examined PGF2a tissue levels
in benign and malignant breast tumours. This is to
our knowledge the first study which has determined
by radioimmunoassay the PGF2a tissue levels in
breast cancers and compared them with histo-
logically proven non-malignant tissues from the
same breast with correlations in terms of
PGF2 mg- 1 protein and cellularity.
Bennett et al. (1975, 1977) using bioassay first
described elevated levels of "prostaglandin-like'
material in extracts of human mammary cancer.
Greaves et al. (1980) performed radioiommunoassay
of PGE and PGF and correlated the results with
tissue weight in a small group of breast cancers
(n= 16). Rolland et al. (1980) determined the PGE2
production from added arachidonic acid in 91
breast cancers. Bishop et al. (1980) and Malachi et
al. (1981) determined PGE2 and Fulton et al. (1982)
PGE2and PGF2a by radioimmunoassay in breast
cancer and correlated the results with tissue wet w.
Watson et al. (1984) measured PGE2 and PGF2a, by
Gas Liquid Chromatography - Mass Spectrometry
in 100 mammary carcinomatas.
Our difference between the PGF2amg-1 protein
levels of cancer tissue and histologically provenPROSTAGLANDIN F2, IN BENIGN AND MALIGNANT BREAST TUMOURS
Table V PGF2, yields from breast cancer in relation to cumulated prognostical
factors.
Variable PGF2a P-value
Lymph nodes pos (28) 12.26+2.65 0.190
neg (25) 17.18+4.15
Lymph nodes pos+tumour size>20mm (19) 12.88+3.65 0.104
neg+tumour size<20mm (16) 18.97+5.67
Lymph nodes pos+tumour size>20mm+undiff (12) 13.60+5.58 0.045
neg+tumour size <20mm+diff (8) 22.95 +9.40
The PG results are given as ngmg - protein, mean+ s.e.m.
The number of evalulated samples is given in brackets.
Undiff=undifferentiated.
Diff =differentiated: some degree of differentiation (small, moderate or high).
non-malignant tissue of the same breast confirms
the findings in the studies cited above.
We also found statistically significant different
PGF2a yields from cancers, compared with fibro-
adenomata, sclero-cystic-disease and normal
glandular breast tissue (Table I).
Stamford et al. (1980) showed an increase of
prostaglandin-like material in extracts of blood
draining breast carcinomatas. In the study of
Powles et al. (1977) 15-keto-13, 14-dihydro-PGE2
was elevated, especially in the group of breast
cancer patients who had metastasis. In the study of
Malachi et al. (1981) the plasma PGE2-metabolite
concentration did not reflect the PGE2 tissue levels,
and no difference was found between the benign
and malignant cases, but both concentrations were
higher than those of the healthy controls. In this
study none of the patients had overt metastasis at
the time of biopsy. We could not demonstrate a
higher level of 15-keto-13, 14-dihydro-PGF2a in the
plasma of the cancer patients than in the SCD
group, or a correlation between the plasma levels of
the PGF2a-metabolite and the PGF2a tissue levels.
Bennett et al. (1977, 1983) showed that the ability
of malignant breast tumours to produce
prostaglandin-like material correlates inversely with
patient survival. Rolland et al. (1980) concluded
that a high PGE2 production occurs very early in
the development of a malignant tumour, and that
an elevated prostaglandin production seems to be
associated with metastasis. This relationship does
not seem to exist for PGF2a tissue levels.
In the present study high PGF2a levels correlate
with good prognostic variables (differentiation,
positive oestrogen and progestagen receptor status,
low mitotic index). Tumours with a good prognosis
(some degree of differentiation, <20mm, no lymph
node metastasis) yielded more PGF2a than did
tumours with a bad prognosis (undifferentiated,
>20mm, lymph node metastasis) Table V),
although the relationships with these uncombined
variables were weak.
We also observed tendencies for higher PGF2a
levels with negative lymphatic permeation, post-
menopausal patients, fibrosis, elastosis and a low
nuclear: cytoplasmic ratio (Table III).
Malachi et al. (1981) found no correlation
between PGE2 tissue levels and survival, histo-
logical type and stage. The data on tumour
recurrence of Bennett et al. (1983) argued against an
important role for PGE2 in bone metastasis, and
Blamey (personal communication) did not find a
correlation between PGE2 and bone metastasis. In
a series of rat mammary carcinomatas PGE2 levels
correlated inversely with metastatic potential
(Kibbey et al., 1979).
Fulton et al. (1982) and Campbell et al. (1983)
concluded that oestrogen receptor- positive tumours
synthesized more PGE2, whereas Rolland et al.
(1980) found a tendency for the opposite. Wilson et
al. (1980) and Watson et al. (1984) found little or no
correlation between prostaglandins and oestrogen
receptor status. In the present study PGF2,
correlated with receptors for steroid hormones.
Host-derived inflammatory cells are thought to
contribute to the PG-production by cancers
(Greaves et al., 1980; Honn et al., 1981a). Bennett et
al. (1980) correlated total "PGE2-equivalents" with
the extent of inflammation and necrosis in X-
irradiated squamous carcinomata of head and neck.
We found no significant relationship between the
PGF2a levels and the intensity of the host cell
reaction, presence of mast cells or necrosis. This
corresponds with the finding that most of the
inflamatory cells were lymphocytes, and that co-
incubation of carcinogen-induced rat bladder
tumour cells with lymphocytes did not significantly
change the PGE2 yield (Owen et al., 1980).
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PGs might be involved in tumour initiation,
tumour promotion, cell proliferation, cell differen-
tiation, the immune response, tumour metastasis
and hypercalcaemia. Initiation of carcinogenesis
most commonly requires oxidation, which can
occur during PG synthesis (Honn, 1981a; Marnett,
1982; Zenser et al., 1982).
Phorbol esters such as TPA (tetradecanoyl
phorbol acetate), are tumour-promoting agents
whose action may involve PGs. TPA can release
arachidonate, PGE2 and PGF2,, (Ashendel, 1979;
Bresnick et al., 1979; Boutwell, 1982).
Views on the role of PGs in tumour growth are
controversial. Some authors claim that increased
PG synthesis represents a part of the homeostatic
response to limit tumour growth. Others claim that
PGs are involved in the initiation and the
enhancement of tumour growth. Furthermore the
effect of prostaglandin synthesis inhibitors on
tumour cell growth, - enhancement or inhibition -
can vary according to the tumour cell type and to
the concentration of the anti-inflammatory drug
used (Karmali, 1980).
Impressive effects of PGs on cells in vitro are the
induction of maturation and differentiation. PGE
regulates proliferation and differentiation of stem
cells in the bone marrow in vitro (Bockman, 1982).
Certain PGs notably PGA, PGD and PGI2, can
induce differentiation in vitro of mouse mammary
carcinoma, neuroblastoma, B16 melanoma and
human malignant melanoma (Jubiz et al., 1979;
Rudland & Warburton, 1982; Prasad, 1982;
Bregman & Meyskens, 1983; Simmet & Jaffe, 1983).
It is also possible that PGs influence the
host/tumour interplay. PGE2 is thought to be a
factor involved in the failure of the immune system
to eliminate tumours (Goodwin, 1981), but it is not
yet known whether inhibition of prostaglandin
synthesis will enhance a putative immune reaction
of the host to all types of tumours (Kelly & Parker,
1979, Stringfellow & Fitzpatrick, 1979; Favalli et al.,
1980).
Investigation into the control of metastasis to
bone and of hypercalcaemia associated with
malignancy was prompted by the finding that some
PGs cause osteolysis. Unfortunately, in man there
are no consistent data proving the effectiveness of
prostaglandin synthesis inhibitors on bone
metastasis and hypercalcaemia (Powles et al., 1982).
Numerous platelet anti-aggregating substances e.g.
apsirin, indomethacin, dipyridamole, flurbiprofen
and benorylate have been investigated as possible
antimetastatic agents with both positive and
negative results (Bennett, 1982; Honn 1981a). Of
considerable interest is the hypothesis proposed by
Honn et al. (1981b) that tumour cells can alter the
TXA2/PGI2 balance in favour of platelet
aggregation. But the extents to which thromboxane
inhibitors or prostacyclines, which reduce platelet
aggregation, are of value in human cancers are not
known.
The present study demonstrates that PGF2a yield
from tumours is high in patients with good
prognosis. However, since other authors (Bennett et
al., 1977, 1983; Rolland, 1980) have suggested that a
high PGE2 production is a bad prognostic index, it
is possible that conversion of PGE2 to PGF2a by
9-keto-reductase explains this relationship. Never-
theless, the presented results question the un-
restricted use of prostaglandin-synthesis-
inhibitors in the treatment of breast cancer.
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